Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME SODIUM versus RESPORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME SODIUM versus RESPORAL.
CEFUROXIME SODIUM vs RESPORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime sodium is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
RESPORAL contains theophylline, a methylxanthine that inhibits phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cAMP and cGMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation and anti-inflammatory effects.
750 mg to 1.5 g IV or IM every 8 hours; maximum 6 g per day.
2 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life: 1.2 hours (range 1-2 hours) in patients with normal renal function; prolonged to 15-22 hours in end-stage renal disease (CrCl <10 mL/min); dosing adjustment required for CrCl <30 mL/min
Terminal half-life is 12 hours (range 10-14 h), supporting twice-daily dosing in most patients.
Renal (95% unchanged via glomerular filtration and tubular secretion); biliary/fecal (minimal, <5%)
Renal excretion accounts for 70% of elimination (30% unchanged), biliary/fecal 20%, and 10% metabolized.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic